The Motley Fool's CAPS investing service is a great way for investors to work together to beat the market -- and maybe get famous while they're at it. Among its features, CAPS lets users blog about their picks, investing strategy, market view, their favorite college football team, or whatever floats their boat.
As the CAPS blogosphere continues to grow, players are adding more great content on a daily basis. To make it easier to find some of the gems out there, I've dug through the past week's posts to find some of CAPS' best insights. Of course, with room for only seven posts here I can't possibly cover all of the great stuff in the CAPS blogosphere. So when you're done here, I highly recommend heading over to CAPS and checking out what some of the other investors have to say.
Prospecting for value on the World Wide Web
Looking for good financial education at the right price? Tak3natheFlood has you covered. He's dug through the free resources available out there on the Internet and listed some of his very favorites. After all, tough markets are a perfect time to get back to the basics. Visit Tak3natheFlood's blog for the list.
HANS and JSDA thoughts
Ready to crack open a cold one in your portfolio? What'll it be? Hansen Natural with its high octane Monster line, or Jones Soda (Nasdaq: JSDA) and its real cane sugar? CAPS blogger rknapton thinks that only one of these two upstart pop sellers should make the cut for business reasons, though both could make the grade on valuation. Click through to rknapton's blog for the full scoop.
Owning the picks and shovels
What in the world does Akamai Technologies (Nasdaq: AKAM) have to do with picks and shovels? CAPS blogger mysoftballcoach can tell you and also give you his take on why the stock is a deal right now. Head over to mysoftballcoach's blog for the down low.
Biotech -- the quest for the perfect market-neutral portfolio
CAPS member EV38biotech is hoping to put together a market-neutral portfolio by going long on four- and five-star-rated biotech stocks, while shorting an equal number of one-star biotech stocks. In this go-round of the portfolio build, Genentech (NYSE: DNA) and ViroPharma (Nasdaq: VPHM) made the long side, while Auxilium Pharmaceuticals ended up on the short side. Head over to EV38biotech's blog for the full portfolio.
Arbitrage opportunities
When a merger is in the works, the sharks start circling. In the recent market shake-up, though, it appears that either the sharks have all been killed off, or there is serious doubt surrounding the acquisitions of Anheuser-Busch (NYSE: BUD) and Rohm & Haas. Just how much is there to potentially be made? Drop by weiwentg's blog and check out this investor's analysis of both deals.
The party's over, Carnival ...
With the recent suspension of the dividend, Carnival is being dropped from TMFHighYield's portfolio. Head over to TMFHighYield's blog for the farewell note.
U.S. auto industry -- the worst industry sales month in the post-World War II era
If you thought it was bad already for U.S. carmakers like GM (NYSE: GM) and Ford (NYSE: F), think again. The sales numbers that came in for October showed that it could get even worse. TMFDeej, who has been bearish on the auto industry for a while, has tackled the auto industry's ugly month of October. Check out his blog for the full scoop.
And that's our roundup for this week. Be sure to check back next week for more great blogging action. In the meantime, why not head over to CAPS and add your two cents to the community pool?
More CAPS Foolishness:
Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.
Terms & Conditions
RSS Headlines
Fool UK